|
1
|
Stratigos A, Garbe C, Lebbe C, Malvehy J,
del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag
P, et al: Diagnosis and treatment of invasive squamous cell
carcinoma of the skin: European consensus-based interdisciplinary
guideline. Eur J Cancer. 51:1989–2007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rogers HW, Weinstock MA, Harris AR,
Hinckley MR, Feldman SR, Fleischer AB and Coldiron BM: Incidence
estimate of nonmelanoma skin cancer in the United States, 2006.
Arch Dermatol. 146:283–287. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Vries E, Trakatelli M, Kalabalikis D,
Ferrandiz L, Ruiz-de-Casas A, Moreno-Ramirez D, Sotiriadis D,
Ioannides D, Aquilina S, Apap C, et al: Known and potential new
risk factors for skin cancer in European populations: A multicentre
case-control study. Br J Dermatol. 167 (Suppl 2):S1–S13. 2012.
View Article : Google Scholar
|
|
4
|
El-Abaseri TB, Fuhrman J, Trempus C,
Shendrik I, Tennant RW and Hansen LA: Chemoprevention of UV
light-induced skin tumorigenesis by inhibition of the epidermal
growth factor receptor. Cancer Res. 65:3958–3965. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sahu N and Grandis JR: New advances in
molecular approaches to head and neck squamous cell carcinoma.
Anticancer Drugs. 22:656–664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cañueto J, Cardeñoso E, García JL,
Santos-Briz Á, Castellanos-Martín A, Fernández-López E, Blanco
Gómez A, Pérez-Losada J and Román-Curto C: Epidermal growth factor
receptor expression is associated with poor outcome in cutaneous
squamous cell carcinoma. Br J Dermatol. 176:1279–1287. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng Y, Su C, Zhao L and Shi Y: mAb
MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI
resistance through two potential therapeutic targets modulation of
MDR1 and autophagy. J Nanobiotechnology. 15:662017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang S, Armstrong EA, Benavente S,
Chinnaiyan P and Harari PM: Dual-agent molecular targeting of the
epidermal growth factor receptor (EGFR): Combining anti-EGFR
antibody with tyrosine kinase inhibitor. Cancer Res. 64:5355–5362.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Corkery B, Crown J, Clynes M and O'Donovan
N: Epidermal growth factor receptor as a potential therapeutic
target in triple-negative breast cancer. Ann Oncol. 20:862–867.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El Guerrab A, Bamdad M, Kwiatkowski F,
Bignon YJ, Penault-Llorca F and Aubel C: Anti-EGFR monoclonal
antibodies and EGFR tyrosine kinase inhibitors as combination
therapy for triple-negative breast cancer. Oncotarget.
7:73618–73637. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan X, Thapa N, Sun Y and Anderson RA: A
kinase-independent role for EGF receptor in autophagy initiation.
Cell. 160:145–160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mizushima N: The pleiotropic role of
autophagy: From protein metabolism to bactericide. Cell Death
Differ. 12 (Suppl 2):S1535–S1541. 2005. View Article : Google Scholar
|
|
14
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Degenhardt K, Mathew R, Beaudoin B, Bray
K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, et al:
Autophagy promotes tumor cell survival and restricts necrosis,
inflammation, and tumorigenesis. Cancer Cell. 10:51–64. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Claerhout S, Verschooten L, Van Kelst S,
De Vos R, Proby C, Agostinis P and Garmyn M: Concomitant inhibition
of AKT and autophagy is required for efficient cisplatin-induced
apoptosis of metastatic skin carcinoma. Int J Cancer.
127:2790–2803. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fung C, Chen X, Grandis JR and Duvvuri U:
EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Cancer Biol Ther. 13:1417–1424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jutten B, Keulers TG, Schaaf MB,
Savelkouls K, Theys J, Span PN, Vooijs MA, Bussink J and Rouschop
KM: EGFR overexpressing cells and tumors are dependent on autophagy
for growth and survival. Radiother Oncol. 108:479–483. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang M, Lee KH, Lee HS, Jeong CW, Kwak C,
Kim HH and Ku JH: Concurrent autophagy inhibition overcomes the
resistance of epidermal growth factor receptor tyrosine kinase
inhibitors in human bladder cancer cells. Int J Mol Sci. 18:2017.
View Article : Google Scholar
|
|
20
|
Liu Z, He K, Ma Q, Yu Q, Liu C, Ndege I,
Wang X and Yu Z: Autophagy inhibitor facilitates gefitinib
sensitivity in vitro and in vivo by activating mitochondrial
apoptosis in triple negative breast cancer. PLoS One.
12:e01776942017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iwai-Kanai E, Yuan H, Huang C, Sayen MR,
Perry-Garza CN, Kim L and Gottlieb RA: A method to measure cardiac
autophagic flux in vivo. Autophagy. 4:322–329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Munafó DB and Colombo MI: A novel assay to
study autophagy: Regulation of autophagosome vacuole size by amino
acid deprivation. J Cell Sci. 114:3619–3629. 2001.PubMed/NCBI
|
|
23
|
Uribe P and Gonzalez S: Epidermal growth
factor receptor (EGFR) and squamous cell carcinoma of the skin:
Molecular bases for EGFR-targeted therapy. Pathol Res Pract.
207:337–342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lewis CM, Glisson BS, Feng L, Wan F, Tang
X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA
and Weber RS: A phase II study of gefitinib for aggressive
cutaneous squamous cell carcinoma of the head and neck. Clin Cancer
Res. 18:1435–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
William WN Jr, Feng L, Ferrarotto R,
Ginsberg L, Kies M, Lippman S, Glisson B and Kim ES: Gefitinib for
patients with incurable cutaneous squamous cell carcinoma: A
single-arm phase II clinical trial. J Am Acad Dermatol.
77:1110–1113.e2. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ono M and Kuwano M: Molecular mechanisms
of epidermal growth factor receptor (EGFR) activation and response
to gefitinib and other EGFR-targeting drugs. Clin Cancer Res.
12:7242–7251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang MH, Lee JH, Chang YJ, Tsai HH, Lin
YL, Lin AM and Yang JC: MEK inhibitors reverse resistance in
epidermal growth factor receptor mutation lung cancer cells with
acquired resistance to gefitinib. Mol Oncol. 7:112–120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jutten B and Rouschop KM: EGFR signaling
and autophagy dependence for growth, survival, and therapy
resistance. Cell Cycle. 13:42–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chou TC and Talalay P: Generalized
equations for the analysis of inhibitions of Michaelis-Menten and
higher-order kinetic systems with two or more mutually exclusive
and nonexclusive inhibitors. Eur J Biochem. 115:207–216. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li YY, Lam SK, Mak JC, Zheng CY and Ho JC:
Erlotinib-induced autophagy in epidermal growth factor receptor
mutated non-small cell lung cancer. Lung Cancer. 81:354–361. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Galluzzi L, Pietrocola F, Levine B and
Kroemer G: Metabolic control of autophagy. Cell. 159:1263–1276.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kabeya Y, Mizushima N, Ueno T, Yamamoto A,
Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a
mammalian homologue of yeast Apg8p, is localized in autophagosome
membranes after processing. EMBO J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Behrends C, Sowa ME, Gygi SP and Harper
JW: Network organization of the human autophagy system. Nature.
466:68–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen J, Zheng H, Ruan J, Fang W, Li A,
Tian G, Niu X, Luo S and Zhao P: Autophagy inhibition induces
enhanced proapoptotic effects of ZD6474 in glioblastoma. Br J
Cancer. 109:164–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han W, Pan H, Chen Y, Sun J, Wang Y, Li J,
Ge W, Feng L, Lin X, Wang X, et al: EGFR tyrosine kinase inhibitors
activate autophagy as a cytoprotective response in human lung
cancer cells. PLoS One. 6:e186912011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dragowska WH, Weppler SA, Wang JC, Wong
LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge
M, et al: Induction of autophagy is an early response to gefitinib
and a potential therapeutic target in breast cancer. PLoS One.
8:e765032013. View Article : Google Scholar : PubMed/NCBI
|
